Evidence map›Paper›PMID 35295757›Full record

SynthesisFrontiers in cellular and infection microbiology2022

Efficacy of Fecal Microbiota Transplantation in Irritable Bowel Syndrome: A Meta-Analysis of Randomized Controlled Trials.

Jie Wu, Liang Lv, Chunlian Wang

Registry-linked trialOpen access · goldAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Frontiers in cellular and infection microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06697119 (Efficacy and Safety of Fecal Microbiota Transplantation in Patients with Irritable Bowel Syndrome), which is not on this map. Cited by 35 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 7 pooled it
10.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06697119 naactive not recruitingnot on this mapstarted 2023, after this paper: background citation

Efficacy and Safety of Fecal Microbiota Transplantation in Patients with Irritable Bowel Syndrome

TypeinterventionalSponsorSeoul National University HospitalRan2023 to 2027Enrolled44ConditionsIrritable Bowel DiseaseArmsFecal Microbial Transplantation
3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 7 syntheses or guidelines pooled it, 65 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Microbes as medicine.Annals of the New York Academy of Sciences · 2024
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Jie WuDepartment of Gastroenterology, The Second Xiangya Hospital of Central South University, Changsha, China.
Liang LvDepartment of Gastroenterology, The Second Xiangya Hospital of Central South University, Changsha, China.
Chunlian WangDepartment of Gastroenterology, The Second Xiangya Hospital of Central South University, Changsha, China.
Second Xiangya Hospital of Central South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Randomized controlled trials (RCTs) have examined the efficacy of fecal microbiota transplantation (FMT) in irritable bowel syndrome (IBS) with inconsistent results. We performed a meta-analysis to assess both the short- and long-term efficacy of FMT in IBS. Methods: MEDLINE, EMBASE, and the Cochrane Central Register were searched through September 2021. RCTs recruiting adult patients with IBS that compared FMT with placebo with dichotomous data of response to therapy were eligible. Dichotomous data were pooled to obtain a relative risk (RR) of symptom not improving after therapy. RR was also pooled for adverse events (AEs). Continuous data were calculated using a mean difference for IBS-Quality of Life (IBS-QoL). GRADE methodology was used to assess quality of evidence. Results: The search strategy generated 658 citations. Seven RCTs comprising 472 patients with IBS were included. FMT was not associated with a significant improvement in global symptom in IBS at 12 weeks in comparison with placebo (RR 0.75, 95% CI 0.43-1.31) with high heterogeneity between studies (I Conclusion: IBS patients may benefit from FMT when administered

Indexed as

Irritable Bowel SyndromeAdultColonoscopyFecal Microbiota TransplantationHumansQuality of LifeRandomized Controlled Trials as TopicTreatment Outcomefecal microbiota transplantationintestinal microbiotairritable bowel syndromemeta-analysismicrobiota

Identifiers

PMID35295757
PMCPMC8919053
OpenAlexW4214644395

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.